Nura Health develops an AI-driven, non-invasive blood test for endometriosis and infertility risk, significantly shortening the diagnostic timeline. This patent-pending solution uses machine learning to analyze biomarkers, achieving diagnostic accuracy comparable to surgical standards. The company provides clinicians and patients with faster, safer insights for personalized reproductive health treatment planning.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Endometriosis diagnosis typically takes 8-12 years, causing prolonged suffering and delayed treatment for women experiencing chronic pelvic pain. This extended timeframe results in significant dissatisfaction and negatively impacts quality of life.
Solution
Nura Health offers a non-invasive blood test that significantly reduces the time to endometriosis diagnosis to just 3-5 days. By leveraging artificial intelligence and machine learning, the test analyzes biomarkers in the blood to identify the presence of endometriosis. This accelerated diagnosis empowers Ob/Gyn and fertility clinics to provide timely and appropriate care through a B2B platform. Nura Health also provides a direct-to-consumer (B2C) platform, enabling women to initiate testing from home and receive results quickly.
Target Audience
The primary target audience includes women experiencing chronic pelvic pain, young women aged 14-25 with period pain, infertile women aged 30-45 with unexplained infertility, and diagnosed women aged 17-49 seeking to monitor endometriosis reoccurrence, as well as Ob/Gyn and fertility clinics.
Features
- Non-invasive blood test for endometriosis diagnosis
- AI and machine learning-powered analysis of biomarkers
- Direct-To-Clinic platform for Ob/Gyn and fertility clinics
- Direct-To-Consumer platform for at-home testing
- Rapid turnaround time of 3-5 days for test results